Burden of Proof: Evaluating the Efficacy of Tumor Mutational Burden (TMB) in Predicting Response to Immune Checkpoint Inhibitors.
作者信息
Newman James, Seetharamu Nagashree, Saif Muhammad Wasif
机构信息
Northwell Health Cancer Institute, Lake Success, NY, USA.
出版信息
Cancer Med J. 2020 Dec;3(Suppl 2):17-21. Epub 2020 Nov 19.
Abstract
摘要
相似文献
1
Burden of Proof: Evaluating the Efficacy of Tumor Mutational Burden (TMB) in Predicting Response to Immune Checkpoint Inhibitors.举证责任：评估肿瘤突变负荷（TMB）预测免疫检查点抑制剂疗效的有效性
Cancer Med J. 2020 Dec;3(Suppl 2):17-21. Epub 2020 Nov 19.
2
A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.一种基于下一代测序的策略，结合微卫星不稳定性和肿瘤突变负担，用于晚期结直肠癌的综合分子诊断。
BMC Cancer. 2021 Mar 16;21(1):282. doi: 10.1186/s12885-021-07942-1.
3
The role of immune checkpoint inhibitors for patients with advanced stage microsatellite stable colorectal cancer and high tumor mutation burden: quantity or quality?免疫检查点抑制剂在晚期微卫星稳定型结直肠癌和高肿瘤突变负担患者中的作用：数量还是质量？
Expert Opin Biol Ther. 2023 Jul-Dec;23(7):595-601. doi: 10.1080/14712598.2023.2226327. Epub 2023 Jun 18.
4
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.超越微卫星检测：肿瘤突变负荷评估可识别可能对免疫检查点抑制有反应的结直肠癌亚组。
J Gastrointest Oncol. 2018 Aug;9(4):610-617. doi: 10.21037/jgo.2018.05.06.
5
Distinctive genomic characteristics in -mutant cancers can potentially predict beneficial clinical outcomes in patients who receive immune checkpoint inhibitor.-突变癌症中独特的基因组特征可能预测接受免疫检查点抑制剂治疗患者的有益临床结果。
Ann Transl Med. 2021 Jan;9(2):129. doi: 10.21037/atm-20-7553.
6
Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.转移性结直肠癌的肿瘤突变负担、微卫星不稳定性和可操作的改变：TRIBE2 研究的下一代测序结果。
Eur J Cancer. 2021 Sep;155:73-84. doi: 10.1016/j.ejca.2021.06.037. Epub 2021 Aug 5.
7
Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.肿瘤突变负担预测免疫检查点抑制剂在结直肠癌中的疗效：系统评价和荟萃分析。
Front Immunol. 2021 Sep 29;12:751407. doi: 10.3389/fimmu.2021.751407. eCollection 2021.
8
Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.1057 例微卫星不稳定高固体肿瘤中 MLH1、PMS2、MSH2 和 MSH6 基因特异性改变与肿瘤突变负担的关系。
Int J Cancer. 2020 Nov 15;147(10):2948-2956. doi: 10.1002/ijc.33115. Epub 2020 Jun 18.
9
Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.分析 17486 例管状胃肠癌中的 DNA 损伤反应基因改变和肿瘤突变负荷：对治疗的启示。
Oncologist. 2019 Oct;24(10):1340-1347. doi: 10.1634/theoncologist.2019-0034. Epub 2019 Apr 30.
10
Microsatellite Instability-High and High Tumor Mutation Burden Frequencies in Urologic Malignancies Off-Label for Immune Checkpoint Inhibitors in Japan: A Retrospective Single-Institutional Cohort.日本泌尿外科恶性肿瘤中微卫星高度不稳定和高肿瘤突变负荷频率在免疫检查点抑制剂的非标签使用中的情况：一项回顾性单机构队列研究
Cureus. 2024 Sep 13;16(9):e69366. doi: 10.7759/cureus.69366. eCollection 2024 Sep.
引用本文的文献
1
Pan-cancer analysis and experimental validation of FPR3 as a prognostic and immune infiltration-related biomarker for glioma.FPR3作为胶质瘤预后及免疫浸润相关生物标志物的泛癌分析与实验验证
Front Genet. 2024 Oct 9;15:1466617. doi: 10.3389/fgene.2024.1466617. eCollection 2024.
2
The prognostic and immunological role of MCM3 in pan-cancer and validation of prognosis in a clinical lower-grade glioma cohort.MCM3在泛癌中的预后及免疫作用以及临床低级别胶质瘤队列中的预后验证
Front Pharmacol. 2024 Apr 18;15:1390615. doi: 10.3389/fphar.2024.1390615. eCollection 2024.
3
Perspectives on Immunotherapy of Metastatic Colorectal Cancer.转移性结直肠癌免疫治疗的观点
Front Oncol. 2021 Jun 9;11:659964. doi: 10.3389/fonc.2021.659964. eCollection 2021.
本文引用的文献
1
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.帕博利珠单抗治疗的晚期实体瘤患者肿瘤突变负荷与结局的相关性：多队列、开放标签、Ⅱ期 KEYNOTE-158 研究的前瞻性生物标志物分析。
Lancet Oncol. 2020 Oct;21(10):1353-1365. doi: 10.1016/S1470-2045(20)30445-9. Epub 2020 Sep 10.
2
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.纳武利尤单抗联合伊匹木单抗治疗晚期黑色素瘤的 5 年生存数据
N Engl J Med. 2019 Oct 17;381(16):1535-1546. doi: 10.1056/NEJMoa1910836. Epub 2019 Sep 28.
3
Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types.评估POLE和POLD1突变作为多种癌症类型免疫治疗结果生物标志物的研究
JAMA Oncol. 2019 Oct 1;5(10):1504-1506. doi: 10.1001/jamaoncol.2019.2963.
4
Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.肿瘤突变负担可预测 MSI-H 转移性结直肠癌对免疫检查点抑制剂的反应。
Ann Oncol. 2019 Jul 1;30(7):1096-1103. doi: 10.1093/annonc/mdz134.
5
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.帕博利珠单抗对比化疗用于未经治疗、PD-L1 表达、局部晚期或转移性非小细胞肺癌（KEYNOTE-042）：一项随机、开放标签、对照、III 期临床试验。
Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.
6
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.利用下一代测序癌症基因 panel 评估血液肿瘤突变负担作为非小细胞肺癌患者免疫治疗的潜在生物标志物。
JAMA Oncol. 2019 May 1;5(5):696-702. doi: 10.1001/jamaoncol.2018.7098.
7
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors.美国食品药品监督管理局批准摘要：帕博利珠单抗用于治疗微卫星高度不稳定实体瘤。
Clin Cancer Res. 2019 Jul 1;25(13):3753-3758. doi: 10.1158/1078-0432.CCR-18-4070. Epub 2019 Feb 20.
8
Tumor mutational load predicts survival after immunotherapy across multiple cancer types.肿瘤突变负荷可预测多种癌症类型免疫治疗后的生存情况。
Nat Genet. 2019 Feb;51(2):202-206. doi: 10.1038/s41588-018-0312-8. Epub 2019 Jan 14.
9
Tumor mutation burden in lung cancer: a new predictive biomarker for immunotherapy or too soon to tell?肺癌中的肿瘤突变负荷：免疫治疗的一种新的预测生物标志物，还是言之尚早？
J Thorac Dis. 2018 Nov;10(Suppl 33):S3994-S3998. doi: 10.21037/jtd.2018.09.35.
10
Methods of measurement for tumor mutational burden in tumor tissue.肿瘤组织中肿瘤突变负荷的测量方法。
Transl Lung Cancer Res. 2018 Dec;7(6):661-667. doi: 10.21037/tlcr.2018.08.02.
Zotero 插件